Chongqing Pharscin Pharmaceutical Co., Ltd.
As of 20 November 2026, for the company name Chongqing Pharscin Pharmaceutical Co., Ltd. as recorded, 3 applications with this name as first applicant are listed as under review at China's CDE; the CDE acceptance records name it as first applicant on 43 records, across 30 drug names; since 23 August 2026, the records list Accepted: 2 applications (NMPA data as of 19 November 2026); the chemical-drug catalogue lists 11 active records with this name as holder; 9 active API registrations list this name as first registered company; 9 further acceptance records name it after the first applicant.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/20.
Drug filings
43 acceptance records as first applicant, grouped into 30 source drug names. Source data as of 2026/11/20.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Lercanidipine Hydrochloride Tablets 1 records · Latest accepted 2026/10/16
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2602549 | Generic | 2026/10/16 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
Clopidogrel Hydrogen Sulphate Tablets 1 records · Latest accepted 2026/09/01
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2601666 | Supplement | 2026/09/01 | Chongqing Pharscin Pharmaceutical Co., Ltd.; Qingdao Huang Hai Pharmaceutical Co., Ltd. romanized | CDE ↗ |
健儿消食口服液 · No verified English name 3 records · Latest accepted 2026/06/25
Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2603000 | Supplement | 2026/06/25 | Chongqing Pharscin Pharmaceutical Co., Ltd.; Henan Ling You Pharma Co., Ltd. romanized | CDE ↗ |
| CYZB2502129 | Supplement | 2025/09/25 | Chongqing Pharscin Pharmaceutical Co., Ltd.; Henan Ling You Pharma Co., Ltd. romanized | CDE ↗ |
| CYZB2501707 | Supplement | 2025/08/08 | Chongqing Pharscin Pharmaceutical Co., Ltd.; Henan Ling You Pharma Co., Ltd. romanized | CDE ↗ |
Apalutamide Tablets 1 records · Latest accepted 2025/09/19
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2503468 | Generic | 2025/09/19 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
Orlistat Capsules 2 records · Latest accepted 2025/05/09
Generic · 2
CX001缓释片 · No verified English name 3 records · Latest accepted 2025/04/17
New drug · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2500394 | New drug | 2025/04/17 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| CXHL2500393 | New drug | 2025/04/17 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| CXHL2500392 | New drug | 2025/04/17 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
螺旋藻胶囊 · No verified English name 1 records · Latest accepted 2024/12/03
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2402383 | Supplement | 2024/12/03 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
上清片 · No verified English name 1 records · Latest accepted 2024/11/26
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2402306 | Supplement | 2024/11/26 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
Buspirone Hydrochloride Tablets 2 records · Latest accepted 2024/10/13
Generic · 2
Vonoprazan Fumarate Tablets 4 records · Latest accepted 2024/09/05
Supplement · 2Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2401388 | Supplement | 2024/09/05 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2401387 | Supplement | 2024/09/05 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2200908 | Generic | 2022/06/20 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2200907 | Generic | 2022/06/20 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
苍耳子鼻炎胶囊 · No verified English name 2 records · Latest accepted 2024/09/03
Supplement · 2
Crizotinib Capsules 1 records · Latest accepted 2024/05/11
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2401414 | Generic | 2024/05/11 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
托吡酯口服溶液 · No verified English name 1 records · Latest accepted 2024/03/01
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2400730 | Generic | 2024/03/01 | Chongqing Pharscin Pharmaceutical Co., Ltd.; Huayi Pharmaceuticals (Anhui) Co., Ltd. | CDE ↗ |
Ruxolitinib Phosphate Tablets 1 records · Latest accepted 2024/01/27
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2400363 | Generic | 2024/01/27 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
小儿咽扁颗粒 · No verified English name 2 records · Latest accepted 2023/07/31
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2301406 | Supplement | 2023/07/31 | Chongqing Pharscin Pharmaceutical Co., Ltd.; Shanxi Mai Di Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYZB2301405 | Supplement | 2023/07/31 | Chongqing Pharscin Pharmaceutical Co., Ltd.; Shanxi Mai Di Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Agomelatine Tablets 1 records · Latest accepted 2023/07/12
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2301877 | Generic | 2023/07/12 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
八味芪龙颗粒 · No verified English name 1 records · Latest accepted 2023/06/29
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2301195 | Supplement | 2023/06/29 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
平消片 · No verified English name 2 records · Latest accepted 2023/06/29
Supplement · 2
胆舒软胶囊 · No verified English name 1 records · Latest accepted 2023/06/29
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2301196 | Supplement | 2023/06/29 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
Penehyclidine Hydrochloride Injection 1 records · Latest accepted 2023/06/05
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2340013 | Supplement | 2023/06/05 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
痛泻宁颗粒 · No verified English name 1 records · Latest accepted 2023/03/15
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2300470 | Supplement | 2023/03/15 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
甘桔冰梅片 · No verified English name 1 records · Latest accepted 2023/03/07
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2300431 | Supplement | 2023/03/07 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
Olmesartan Medoxomil and Amlodipine Besylate Tablets 1 records · Latest accepted 2023/02/02
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2300201 | Supplement | 2023/02/02 | Chongqing Pharscin Pharmaceutical Co., Ltd.; Jiangxi Shimei Pharmaceutical Co., Ltd | CDE ↗ |
Rasagiline Mesylate Tablets 2 records · Latest accepted 2022/06/14
Generic · 2
复方聚乙二醇电解质散(III) · No verified English name 1 records · Latest accepted 2022/05/07
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2200711 | Generic | 2022/05/07 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
注射用奥美拉唑钠(静脉滴注) · No verified English name 1 records · Latest accepted 2022/04/12
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2250206 | Supplement | 2022/04/12 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
茶愈胶囊 · No verified English name 1 records · Latest accepted 2021/09/23
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2101840 | Supplement | 2021/09/23 | Chongqing Pharscin Pharmaceutical Co., Ltd.; Liaoning Yi Bang Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Omeprazole and Sodium Bicarbonate Capsules 1 records · Latest accepted 2021/09/16
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2101843 | Supplement | 2021/09/16 | Chongqing Pharscin Pharmaceutical Co., Ltd.; Beijing Bai Ao Pharma Co., Ltd. romanized | CDE ↗ |
Gabexate Mesilate For Injection 1 records · Latest accepted 2021/09/14
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2150867 | Supplement | 2021/09/14 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
盐酸特拉唑嗪胶囊 · No verified English name 1 records · Latest accepted 2021/01/29
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2150081 | Supplement | 2021/01/29 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
Changes in the last 90 days
2 events from 2026/08/23 to 2026/11/20. CDE data as of 2026/11/20; NMPA data as of 2026/11/19.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Accepted: 2 applications
- 2026/10/16Accepted
Lercanidipine Hydrochloride Tablets
CYHS2602549
Fact date: 2026/10/16 · Date added to this site: 2026/10/22
View source ↗ - 2026/09/01Accepted
Clopidogrel Hydrogen Sulphate Tablets
CYHB2601666
Fact date: 2026/09/01 · Date added to this site: 2026/10/22
View source ↗
Under review
3 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/20.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Lercanidipine Hydrochloride Tablets | CYHS2602549 | Generic | 2026/10/16 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| Apalutamide Tablets | CYHS2503468 | Generic | 2025/09/19 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| Ruxolitinib Phosphate Tablets | CYHS2400363 | Generic | 2024/01/27 | Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
Catalogue holder records
11 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/20. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | NMPA approval no. | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Buspirone Hydrochloride Tablets | Chongqing Pharscin Pharmaceutical Co., Ltd. | Chongqing Pharscin Pharmaceutical Co., Ltd. | 国药准字H20263674 | 2026/03/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Buspirone Hydrochloride Tablets | Chongqing Pharscin Pharmaceutical Co., Ltd. | Chongqing Pharscin Pharmaceutical Co., Ltd. | 国药准字H20263675 | 2026/03/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rasagiline Mesylate Tablets | Chongqing Pharscin Pharmaceutical Co., Ltd. | Chongqing Pharscin Pharmaceutical Co., Ltd. | 国药准字H20243081 | 2024/01/23 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Penehyclidine Hydrochloride Injection | Chongqing Pharscin Pharmaceutical Co., Ltd. | Chongqing Pharscin Pharmaceutical Co., Ltd. | 国药准字H20193271 | 2024/01/05 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| 复方聚乙二醇电解质散(III) · No verified English name | Chongqing Pharscin Pharmaceutical Co., Ltd. | Chongqing Pharscin Pharmaceutical Co., Ltd. | 国药准字H20234400 | 2023/10/27 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Omeprazole Sodium for Injection | Chongqing Pharscin Pharmaceutical Co., Ltd. | Chongqing Pharscin Pharmaceutical Co., Ltd. | 国药准字H20163061 | 2023/04/11 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Omeprazole Sodium for Injection | Chongqing Pharscin Pharmaceutical Co., Ltd. | Chongqing Pharscin Pharmaceutical Co., Ltd. | 国药准字H20163061 | 2023/04/11 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Gabexate Mesilate For Injection | Chongqing Pharscin Pharmaceutical Co., Ltd. | Chongqing Pharscin Pharmaceutical Co., Ltd. | 国药准字H20153228 | 2022/08/01 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| 盐酸特拉唑嗪胶囊 · No verified English name | Chongqing Pharscin Pharmaceutical Co., Ltd. | Chongqing Pharscin Pharmaceutical Co., Ltd. | 国药准字H10980127 | 2022/03/08 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Vonoprazan Fumarate Tablets | Chongqing Pharscin Pharmaceutical Co., Ltd. | Chongqing Pharscin Pharmaceutical Co., Ltd. | 国药准字H20243878 | 2024/06/04 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Vonoprazan Fumarate Tablets | Chongqing Pharscin Pharmaceutical Co., Ltd. | Chongqing Pharscin Pharmaceutical Co., Ltd. | 国药准字H20243879 | 2024/06/04 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
9 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/20.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 阿戈美拉汀 · No verified English name | Chongqing Pharscin Pharmaceutical Co., Ltd. | Y20230000351 | A | 2024/11/20 | CDE ↗ |
| 甲磺酸雷沙吉兰 · No verified English name | Chongqing Pharscin Pharmaceutical Co., Ltd. | Y20220000136 | A | 2023/12/28 | CDE ↗ |
| 铝碳酸镁 · No verified English name | Chongqing Pharscin Pharmaceutical Co., Ltd. | Y20190009445 | A | 2024/10/09 | CDE ↗ |
| 聚维酮碘 · No verified English name | Chongqing Pharscin Pharmaceutical Co., Ltd. | Y20190008078 | A | 2025/09/24 | CDE ↗ |
| 甘草酸二铵 · No verified English name | Chongqing Pharscin Pharmaceutical Co., Ltd. | Y20190007988 | A | 2025/09/02 | CDE ↗ |
| 甲磺酸加贝酯 · No verified English name | Chongqing Pharscin Pharmaceutical Co., Ltd. | Y20190006610 | A | 2026/02/05 | CDE ↗ |
| 阿魏酸钠 · No verified English name | Chongqing Pharscin Pharmaceutical Co., Ltd. | Y20190001543 | A | — | CDE ↗ |
| 铝碳酸镁 · No verified English name | Chongqing Pharscin Pharmaceutical Co., Ltd. | Y20180001477 | A | 2024/06/21 | CDE ↗ |
| 盐酸戊乙奎醚 · No verified English name | Chongqing Pharscin Pharmaceutical Co., Ltd. | Y20170001628 | A | 2024/08/07 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
9 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/20.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Buspirone Hydrochloride Tablets | CYHB2601647 | Supplement | 2026/08/27 | Yuan Da Pharmaceuticals (Xian) Co., Ltd. romanized; Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| Buspirone Hydrochloride Tablets | CYHB2601646 | Supplement | 2026/08/27 | Yuan Da Pharmaceuticals (Xian) Co., Ltd. romanized; Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| Orlistat Capsules | CYHB2601547 | Supplement | 2026/08/13 | Chongqing Rui En Pharmaceuticals Co., Ltd. romanized; Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| Orlistat Capsules | CYHB2500485 | Supplement | 2025/03/08 | Chongqing Xing Chuang Pharmaceuticals Co., Ltd. romanized; Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| Empagliflozin Tablets | CYHS2401721 | Generic | 2024/06/07 | You Hua Pharmaceuticals Technology Co., Ltd. romanized; Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| Empagliflozin Tablets | CYHS2401720 | Generic | 2024/06/07 | You Hua Pharmaceuticals Technology Co., Ltd. romanized; Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| 二甲双胍恩格列净片(VI) · No verified English name | CYHS2302607 | Generic | 2023/09/27 | Chongqing Xi Wei Pharmaceuticals Technology Co., Ltd. romanized; Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| 二甲双胍恩格列净片(I) · No verified English name | CYHS2302606 | Generic | 2023/09/27 | Chongqing Xi Wei Pharmaceuticals Technology Co., Ltd. romanized; Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
| 孟鲁司特钠颗粒 · No verified English name | CYHS2201053 | Generic | 2022/07/12 | You Hua Pharmaceuticals Technology Co., Ltd. romanized; Chongqing Pharscin Pharmaceutical Co., Ltd. | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/20
- Chemical-drug catalogue
- Last successful update: 2026/11/20
- API registrations
- Last successful update: 2026/11/20
- NMPA drug delivery notices
- Last successful update: 2026/11/19
Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.